Not a good buy right now: trend structure is still bearish (SMA_200 > SMA_20 > SMA_5) and Intellectia signals show no strong edge today.
Options market is extremely call-skewed but also very illiquid with ultra-high IV, which reads more like speculative positioning than reliable bullish conviction.
With earnings on 2026-02-13 (after hours) and weak recent financials (no revenue, widening losses), the near-term risk/reward is unattractive for an impatient buyer.
Best action now: avoid/exit and reassess only if price reclaims the pivot (~0.792) and holds above it with improving momentum.
Technical Analysis
Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), suggesting rallies are more likely to be sold.
Momentum: MACD histogram is positive and expanding (0.00401), indicating a short-term bounce attempt, but it conflicts with the bearish moving-average stack.
RSI(6)=43: neutral-to-weak, not signaling an oversold reversal.
Key levels:
Pivot: 0.792 (needs reclaim to improve the setup)
Support: 0.745 (S1), then 0.717 (S2)
Resistance: 0.838 (R1), then 0.867 (R2)
Probabilistic pattern read: similar-pattern stats imply ~60% chance of -1.28% next day, +1.15% next week, +8.95% next month—near-term still choppy/weak.
Positioning: Put/call OI ratio 0.02 (calls dominate open interest), which is directionally bullish if liquidity/volume confirms.
Liquidity/confirmation: today’s options volume is essentially nonexistent (total volume=1; put volume=0), so sentiment inference is low-confidence.
Volatility: 30D IV ~502% with IV percentile ~75 (elevated). This points to highly speculative pricing and large implied move expectations.
Open interest: call OI 9,016 vs put OI 166; todays open interest (9,182) is elevated vs 30D avg (indicator shows ~104.65), but without volume it looks like stale positioning rather than fresh demand.
Technical Summary
Sell
9
Buy
1
Positive Catalysts
Near-term catalyst: Earnings for QDec 2025 on 2026-02-13 after hours (can produce a sharp move in either direction).
Short-term momentum is attempting to turn up (MACD histogram positive and expanding).
Trading trends: hedge funds and insiders flagged as neutral (no recent heavy distribution signals in the provided data).
Neutral/Negative Catalysts
keeps the stock in a downtrend regime.
Financial Performance
Latest quarter provided: 2025/Q4.
Revenue: 0 (no improvement in operating scale; YoY change shown as 0.00%).
Profitability: Net income -7,959,288 (down -30.88% YoY), indicating losses widened.
Takeaway: growth trend remains weak with no revenue base and worsening bottom-line performance, which reduces the attractiveness of buying ahead of earnings.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, implying limited/unclear current Wall Street coverage in this dataset.
Wall Street-style pros (based on provided facts): potential for sharp upside moves around catalysts (earnings) and some short-term momentum improvement (MACD).
Wall Street-style cons: no revenue, widening losses, bearish longer-term technical structure, and extremely speculative options pricing (very high IV) with poor liquidity.
Politicians/Influential figures: no recent congress trading data available in the last 90 days (no signal from that channel).
Wall Street analysts forecast CTXR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTXR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CTXR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTXR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 0.712
Low
0
Averages
0
High
0
0
Current: 0.712
Low
0
Averages
0
High
0
D. Boral Capital
D. Boral Capital
Buy
downgrade
$9 -> $6
AI Analysis
2025-06-10
Reason
D. Boral Capital
D. Boral Capital
Price Target
$9 -> $6
AI Analysis
2025-06-10
downgrade
Buy
Reason
D. Boral Capital lowered the firm's price target on Citius Pharmaceuticals to $6 from $9 and keeps a Buy rating on the shares. The firm cites dilution for the target cut after the company announced a registered direct offering totaling up to $15.8M in gross proceeds.
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim
Price Target
2025-05-23
downgrade
Buy
to
Hold
Reason
Maxim downgraded Citius Pharmaceuticals to Hold from Buy.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CTXR
